海泰新光(688677.SH)2025年度归母净利润1.72亿元，同比增长26.79%

Core Viewpoint - The company reported a strong performance for the fiscal year 2025, with significant growth in both revenue and net profit, indicating robust operational stability despite external challenges [1]. Financial Performance - The company achieved an operating revenue of 602.61 million yuan, representing a year-on-year increase of 36.08% [1]. - The net profit attributable to the parent company was 171.60 million yuan, reflecting a year-on-year growth of 26.79% [1]. - The growth in net profit and net profit excluding non-recurring items was 27% and 29% respectively [1]. Operational Strategy - In response to the risks posed by U.S. tariffs on Chinese goods, the company has actively adjusted its production strategies, with most products now being manufactured and shipped from its factories in the U.S. and Thailand [1]. - The company has coordinated production between domestic and overseas factories to mitigate the impact of tariffs, leading to a significant increase in the export scale of medical endoscope products [1]. - There has been an increased investment in research and market development for the company's proprietary brand complete machine products, laying a foundation for the growth of the complete machine business [1]. - The optical business segment has also experienced rapid sales growth during the reporting period [1].